Patent application number | Description | Published |
20080269154 | Novel neurotrophic factor protein and uses thereof - The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes. | 10-30-2008 |
20090282495 | NEUROTROPHIC FACTOR MANF AND USES THEREOF - The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury. | 11-12-2009 |
20100285045 | Novel Neurotrophic Factor Protein and Uses Thereof - The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes. | 11-11-2010 |
20110152346 | Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids - The invention is concerned with the use of oligonucleotide analogs that contain specifically modified DNA bases to be used in hybridization of nucleic acids, polymerase chain reaction (PCR) and siRNA-mediated gene silencing (RNAi). | 06-23-2011 |
20110171287 | Use of Oligonucleotides with Modified Bases as Antiviral Agents - The present invention relates to the use of oligonucleotides having modified nucleobases to inhibit gene expression and/or replication of viruses in a subject. The modified nucleobases may be mercapto-modified bases or hydroxy-modified nucleobases. It is contemplated that the oligonucleotides further comprise a nuclease complex which enhances anti-viral activity of the oligonucleotides. | 07-14-2011 |
20110251132 | TREATMENT WITH A PHARMACEUTICAL COMPOSITION COMPRISING MANF2 NUCLEIC ACID - A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof. | 10-13-2011 |
20120171279 | STRONGLY BOUND BASE-MODIFIED OLIGONUCLEOTIDES - The present invention provides compounds having a chelating moiety and an oligonucleotide sequence wherein the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. The disclosed compounds are suitable for antisense therapy. The chelating moiety can be complexed to an ion of a lanthanide metal. These compounds are efficient translation inhibitors of nucleic acids and have increased binding affinity for target nucleic acids. The invention also includes compositions and methods of using these compositions as antisense therapy. | 07-05-2012 |
20130030180 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators - Disclosed are compounds and methods for treating neurological and other disorders by administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for GFRα receptor molecules, which can be mimetics of glial-derived neurotrophic factor (GDNF) family ligands (GFLs), GFRα/RET signaling pathway agonists, and/or direct RET agonists (activators). | 01-31-2013 |
20130274186 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 10-17-2013 |
20140259192 | TRANSGENIC ANIMAL COMPRISING A DELETION OR FUNCTIONAL DELETION OF THE 3'UTR OF AN ENDOGENOUS GENE - The present invention relates to the fields of knockout (KO) animal production. The invention is directed to a transgenic KO animal comprising a heterozygous or homozygous deletion or functional deletion of the gene's native 3′ untranslated region (3′UTR) at least in one of its endogenous gene loci, wherein the disrupted endogenous gene is transcribed into an m RNA without its native 3′UTR. Instead, a 3′UTR of choice, knocked in by the experimenter, is transcribed into an m RNA. The 3′UTR KO animals provide a new approach to study gene function as they enable to overexpress the gene products what are negatively regulated via their 3′UTR-s exclusively in those cells that already transcribe the gene, thereby avoiding the misexpression problem present in the animals produced by conventional transgenesis methods. The invention is further directed to KO animals, in which the gene with deletion of 3′UTR is GDNF, NGF or BDNF. | 09-11-2014 |
20150020222 | NEUROTROPHIC FACTOR MANF AND USES THEREOF - The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury. | 01-15-2015 |